Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6354
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy? ; volume:14 ; number:5 ; day:12 ; month:10 ; year:2012 ; pages:1-8 ; date:10.2012
Arthritis Research & Therapy ; 14, Heft 5 (12.10.2012), 1-8, 10.2012
- Urheber
-
Saad, Carla GS
- Beteiligte Personen und Organisationen
-
Ribeiro, Ana CM
Moraes, Julio CB
Takayama, Liliam
Goncalves, Célio R.
Rodrigues, Marcelo B.
de Oliveira, Ricardo M.
Silva, Clovis A.
Bonfá, Eloísa
Pereira, Rosa MR
SpringerLink (Online service)
- DOI
-
10.1186/ar4055
- URN
-
urn:nbn:de:1111-2016050323842
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:48 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Saad, Carla GS
- Ribeiro, Ana CM
- Moraes, Julio CB
- Takayama, Liliam
- Goncalves, Célio R.
- Rodrigues, Marcelo B.
- de Oliveira, Ricardo M.
- Silva, Clovis A.
- Bonfá, Eloísa
- Pereira, Rosa MR
- SpringerLink (Online service)
Ähnliche Objekte (12)
Efficacy of anti–tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta–analysis
Serum sclerostin as a biomarker of disease activity in ankylosing spondylitis in correlation with radiographic imaging
Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy
Andersson lesion in ankylosing spondylitis
Surgical treatment of ankylosing spondylitis deformity
Secukinumab: A Review in Ankylosing Spondylitis
Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study
Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?
Factors associated with cause-specific discontinuation of long-term anti-tumor necrosis factor agent use in patients with ankylosing spondylitis: a retrospective cohort study
ANKHvariants associated with ankylosing spondylitis: gender differences
Association between ankylosing spondylitis and m6A methylation
Atherosclerosis in Egyptian patients with ankylosing spondylitis
Efficacy of anti–tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta–analysis
Serum sclerostin as a biomarker of disease activity in ankylosing spondylitis in correlation with radiographic imaging
Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy
Andersson lesion in ankylosing spondylitis
Surgical treatment of ankylosing spondylitis deformity
Secukinumab: A Review in Ankylosing Spondylitis
Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study
Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?
Factors associated with cause-specific discontinuation of long-term anti-tumor necrosis factor agent use in patients with ankylosing spondylitis: a retrospective cohort study
ANKHvariants associated with ankylosing spondylitis: gender differences
Association between ankylosing spondylitis and m6A methylation
Atherosclerosis in Egyptian patients with ankylosing spondylitis
Efficacy of anti–tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta–analysis
Serum sclerostin as a biomarker of disease activity in ankylosing spondylitis in correlation with radiographic imaging
Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy
Andersson lesion in ankylosing spondylitis
Surgical treatment of ankylosing spondylitis deformity
Secukinumab: A Review in Ankylosing Spondylitis
Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study
Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS)?
Factors associated with cause-specific discontinuation of long-term anti-tumor necrosis factor agent use in patients with ankylosing spondylitis: a retrospective cohort study
ANKHvariants associated with ankylosing spondylitis: gender differences
Association between ankylosing spondylitis and m6A methylation